Claims

1. A transdermal therapeutic system (TTS) for continuous administration of pramipexol, comprising a backing layer and at least one active ingredient-containing polymer layer which comprises the active ingredient pramipexol, wherein the active ingredient-containing polymer layer comprises at least one pressure-sensitive adhesive polymer from the group of silicones (polydimethylsiloxanes), of polyisobutylenes, of polybutenes, of styrene-isoprene-styrene block copolymers in combination with resins, and of carboxyl group-free polyacrylates, where the active ingredient pramipexol is present therein in a proportion of between 10 and 40 % by weight.

2. The TTS as claimed in claim 1, which comprises a further pressure-sensitive adhesive layer, an additional membrane which controls the rate of release of pramipexol, an additional active ingredient-containing layer or an additional supporting layer.

3. The TTS as claimed in claim 1 or 2, wherein the pressure-sensitive adhesive polymer is a carboxyl group-free polyacrylate which can be prepared by polymerization of a monomer mixture of at least one acrylic ester or methacrylic ester.

4. The TTS as claimed in claim 3, wherein the monomer mixture comprises at least one acrylic ester or methacrylic ester with linear, branched or cyclic aliphatic C_1-C_{12} substituents without other functional groups.

5. The TTS as claimed in claim 3 or 4, wherein the monomer mixture additionally comprises at least one hydroxyl group-containing acrylic ester or one hydroxyl group-containing methacrylic ester in a proportion by weight of less than 10 %.

6. The TTS as claimed in one or more of claims 3 to 5, wherein the monomer mixture additionally comprises vinyl acetate in a proportion by weight of less than 50 %, preferably less than 25 % and particularly preferably between 0 and 5 %.

7. The TTS as claimed in one or more of the preceding claims, wherein the active ingredient pramipexol is present in the active ingredient-containing polymer layer in dissolved, emulsified and/or dispersed form.

8. The TTS as claimed in one or more of the preceding claims, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer, *R*-(+) enantiomer or racemic mixture of these two enantiomers in the active ingredient-containing polymer layer.

9. The TTS as claimed in one or more of the preceding claims, wherein the active ingredient pramipexol is present as free base, as hydrate, solvate and/or pharmaceutically acceptable salt in the active ingredient-containing polymer layer.

10. The TTS as claimed in one or more of the preceding claims, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer in the form of the

free base in the active ingredient-containing polymer layer.

11. The TTS as claimed in one or more of the preceding claims, which is able to deliver the active ingredient pramipexol continuously to a patient's skin over a period of from 4 to 7 days.

12. The TTS as claimed in one or more of the preceding claims, which is able to release the active ingredient pramipexol with a flux rate greater than 5 $\mu g/cm^2$ h over the period between 24 hours after administration to 168 h after administration.

13. The TTS as claimed in one or more of the preceding claims, which is able to release the active ingredient pramipexol with a flux rate greater than 5 $\mu g/cm^2$ h over the period between 24 hours after administration to 72 h after administration.

14. The TTS as claimed in one or more of the preceding claims, wherein the active ingredient pramipexol is present therein in a proportion of between 10 and 25 % by weight.

15. The TTS as claimed in one or more of the preceding claims, wherein the daily delivery rate of pramipexol is between 0.1-10 mg, preferably between 0.5-4.5 mg.